Pav Rishiraj on pharmacovigilance
Updated: Jan 25
GOLD Nugget: bonus episode
This GOLD Nugget episode sees Helena reflect on some of the best insights offered by Pav Rishiraj, Director and Head of Pharmacovigilance at Ipsen.
Helena shares some of Pav's thoughts on how the often under-recognised field of pharmacovigilance has changed – particularly its rapid evolution during the COVID-19 pandemic – and its importance as a strategic enabler, as well as Pav's advice on what pharma should do to ensure teams feel valued and integral to the businesses they serve.
Look out for the launch of Season 4 on 7 February, as well as the much-anticipated 2023 pharma forecast coming next week – it’s not one to be missed!
A little more on GOLD’s guest…
An expert in the pharmacovigilance field, and with over 20 years of experience under his belt, Pav Rishiraj, Director and Head of Pharmacovigilance at Ipsen, has held a multitude of different positions at various pharma companies such as Merck KGaA, Sandoz and now Ipsen, across drug and patient safety. With a degree in biomedical sciences and a master of science in pharmacology, he is also currently the Chair of the ABPI Pharmacovigilance Expert Network and a Member of the International Society of Pharmacovigilance.
Additional resources
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Pav’s full episode: Pharmacovigilance past, present and future
And do check out GOLD’s next issue, published on 14 February 2023, for more medical affairs insights. Subscribe for free to receive it directly into your inbox!
